Sandoz Group (OTCMKTS:SDZNY) Downgraded to Hold Rating by Barclays

Sandoz Group (OTCMKTS:SDZNY) was downgraded by equities research analysts at Barclays from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

Separately, Jefferies Financial Group upgraded Sandoz Group from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy”.

Sandoz Group Stock Performance

Shares of SDZNY opened at $90.62 on Thursday. The stock has a 50-day moving average of $79.14 and a two-hundred day moving average of $69.32. The company has a quick ratio of 0.82, a current ratio of 1.29 and a debt-to-equity ratio of 0.62. Sandoz Group has a one year low of $35.61 and a one year high of $94.15.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.